IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v7y2016i1d10.1038_ncomms13166.html
   My bibliography  Save this article

Targeted inhibition of the COP9 signalosome for treatment of cancer

Author

Listed:
  • Anita Schlierf

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG)

  • Eva Altmann

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG)

  • Jean Quancard

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG)

  • Anne B. Jefferson

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG
    Present address: Centers for Therapeutic Innovation, Pfizer Inc., San Francisco, California 94158, USA)

  • René Assenberg

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG
    Present address: Janssen Biologics BV, 2333CB Leiden, The Netherlands)

  • Martin Renatus

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG)

  • Matthew Jones

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG)

  • Ulrich Hassiepen

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG)

  • Michael Schaefer

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG)

  • Michael Kiffe

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG)

  • Andreas Weiss

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG)

  • Christian Wiesmann

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG)

  • Richard Sedrani

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG)

  • Jörg Eder

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG)

  • Bruno Martoglio

    (Novartis Institutes for Biomedical Research, Novartis Pharma AG
    Present address: Pharma Research & Early Development, Roche Innovation Center Basel, 4070 Basel, Switzerland)

Abstract

The COP9 signalosome (CSN) is a central component of the activation and remodelling cycle of cullin-RING E3 ubiquitin ligases (CRLs), the largest enzyme family of the ubiquitin–proteasome system in humans. CRLs are implicated in the regulation of numerous cellular processes, including cell cycle progression and apoptosis, and aberrant CRL activity is frequently associated with cancer. Remodelling of CRLs is initiated by CSN-catalysed cleavage of the ubiquitin-like activator NEDD8 from CRLs. Here we describe CSN5i-3, a potent, selective and orally available inhibitor of CSN5, the proteolytic subunit of CSN. The compound traps CRLs in the neddylated state, which leads to inactivation of a subset of CRLs by inducing degradation of their substrate recognition module. CSN5i-3 differentially affects the viability of tumour cell lines and suppresses growth of a human xenograft in mice. Our results provide insights into how CSN regulates CRLs and suggest that CSN5 inhibition has potential for anti-tumour therapy.

Suggested Citation

  • Anita Schlierf & Eva Altmann & Jean Quancard & Anne B. Jefferson & René Assenberg & Martin Renatus & Matthew Jones & Ulrich Hassiepen & Michael Schaefer & Michael Kiffe & Andreas Weiss & Christian Wie, 2016. "Targeted inhibition of the COP9 signalosome for treatment of cancer," Nature Communications, Nature, vol. 7(1), pages 1-10, December.
    • Handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms13166
    DOI: 10.1038/ncomms13166
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/ncomms13166
    File Function: Abstract
    Download Restriction: no
    File URL: https://libkey.io/10.1038/ncomms13166?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Namrata Kumar & Arjan F. Theil & Vera Roginskaya & Yasmin Ali & Michael Calderon & Simon C. Watkins & Ryan P. Barnes & Patricia L. Opresko & Alex Pines & Hannes Lans & Wim Vermeulen & Bennett Houten, 2022. "Global and transcription-coupled repair of 8-oxoG is initiated by nucleotide excision repair proteins," Nature Communications, Nature, vol. 13(1), pages 1-16, December.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:7:y:2016:i:1:d:10.1038_ncomms13166. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.